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We have studied by PCR and DNA sequencing the presence of the qnrA, qnrB, qnrS, aac(6)-Ib-cr, qepA, intI1,
and ISCR1 genes in 200 clinical isolates of Enterobacter cloacae (n  153) and E. aerogenes (n  47) consec-
utively collected between January 2004 and October 2005 in two hospitals located in Santander (northern
Spain) and Seville (southern Spain). Mutations in the quinolone resistance-determining region of gyrA and
parC also were investigated in organisms containing plasmid-mediated quinolone resistance genes. The isolates
had different resistant phenotypes, including AmpC hyperproduction, extended-spectrum -lactamase
production, resistance or decreased susceptibility to quinolones, and/or resistance to aminoglycosides.
Among the 116 E. cloacae isolates from Santander, qnrS1, qnrB5, qnrB2, and aac(6)-Ib-cr were detected in
22 (19%), 1 (0.9%), 1 (0.9%), and 3 (2.6%) isolates, respectively. Twenty-one, 17, and 2 qnrS1-positive
isolates also contained blaLAP-1, intI1, and ISCR1, respectively. A qnrB7-like gene was detected in one E.
aerogenes isolate from Santander. No plasmid-mediated quinolone resistance gene was detected in the
isolates from Seville. The qnrS1-containing isolates corresponded to four pulsed-field gel electrophoresis
patterns and showed various levels of resistance to quinolones. Six isolates were susceptible to nalidixic
acid and presented reduced susceptibility to ciprofloxacin. The qnrS1 gene was contained in a conjugative
plasmid of ca. 110 kb, and when the plasmid was transferred to recipient strains that did not have a
specific mechanism of quinolone resistance, the ciprofloxacin MICs ranged from 0.047 to 0.125 g/ml.
Resistance to quinolones in enterobacteria is increasing
worldwide (8, 24). Previous studies have demonstrated that in
this group of organisms, multiple mechanisms are involved in
this problem, including altered type II topoisomerases, de-
creased permeability, increased active efflux, target protection,
and drug modification (8, 18, 33). Most of the genes coding for
these mechanisms are of chromosomal origin, but since 1998,
when qnrA1 was discovered in a clinical isolate of K. pneu-
moniae from the United States (18), several plasmid-mediated
quinolone resistance (PMQR) genes (9) have been reported
from clinical isolates, including new qnrA variants, multiple
qnrB and qnrS alleles, qnrC, qnrD, aac(6)-Ib-cr, and two qepA
alleles (4, 8, 17, 44).
Qnr proteins protect type II topoisomerases from quinolone
attack (38, 39). Aac(6)-Ib-cr modifies quinolones containing a
piperazinyl group (31), and QepA proteins are involved in
active efflux (25). Plasmid-borne genes involved in quinolone
resistance cause low-level resistance to quinolones (18, 29) and
have an additive effect on the level of resistance caused by
other mechanisms (19, 28).
qnrA has been identified in complex sul1-type integrons of
the In4 family (39). These integrons contain the ISCR1 se-
quence (37), which codes for a recombinase involved in the
mobilization of antibiotic resistance genes in its proximity. The
qnrB gene also is associated with ISCR1 as well as with another
presumed recombinase, Orf1005 (11). qnrS is not part of an
integron, but it often is bracketed by inverted repeats with
insertion sequence-like structures (7).
PMQR genes have been found worldwide in multiple species
of enterobacteria (18, 29), being particularly frequent in En-
terobacter (more often E. cloacae) (10, 12, 16, 22, 23, 30, 32, 35,
42), Klebsiella pneumoniae (10, 16, 25, 30, 32, 35, 43), and
Escherichia coli (16, 25, 30, 32). Interestingly, on some occa-
sions more than one PMQR gene has been identified in the
same organism (18, 29).
In a previous study by our group (unpublished data), we did
not detect PMQR genes in K. pneumoniae or in E. coli, but we
identified the qnrA1 gene in one isolate of E. cloacae and one
of Citrobacter freundii from a single patient in Santander.
In the study reported here, we focused on the detection of
qnrA, qnrS, qnrB, aac(6)-Ib-cr, or qepA in E. cloacae and E.
aerogenes, the two more clinically relevant species in the genus
Enterobacter. The recently described qnrC (43) and qnrD (4)
genes were not included in this study, as these descriptions
were not known when the study was planned. The study also
aimed to compare the incidence of these genes in two different
geographical locations: Santander (northern Spain) and Seville
(southern Spain).
MATERIALS AND METHODS
Bacteria. We evaluated 200 clinical isolates (1 per patient) of E. cloacae and
E. aerogenes collected at the University Hospital Marqués de Valdecilla in San-
tander (138 isolates: 116 E. cloacae and 22 E. aerogenes) and the University
Hospital Virgen Macarena in Seville (62 isolates: 37 E. cloacae and 25 E. aero-
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genes) between January 2004 and October 2005. The organisms were selected as
consecutive isolates presenting resistance to -lactams (including AmpC hyper-
production or extended-spectrum -lactamase production), resistance or de-
creased susceptibility to quinolones, and/or resistance to aminoglycosides. Iden-
tification and preliminary susceptibility testing were performed by the MicroScan
WalkAway 96 system (Dade Behring, West Sacramento, CA) in Santander and
by the Vitek 2 system (bioMérieux, Hazelwood, MO) in Seville. E. coli ATCC
25922 and ATCC 35218 and Pseudomonas aeruginosa ATCC 27853 were rou-
tinely used in the two centers for quality control purposes. Results obtained with
Etest strips of ciprofloxacin were controlled using E. coli ATCC 25922 and P.
aeruginosa 27853, those of nalidixic acid with E. coli ATCC 25922, and those of
ticarcillin-clavulanate with E. coli ATCC 35218, by testing them in parallel to
clinical isolates.
PCR amplification and DNA sequencing. All 200 isolates were screened by
PCR. The corresponding primers and expected amplicon sizes are presented in
Table 1. Genomic DNA was extracted using the InstaGene matrix kit (Bio-Rad,
Madrid, Spain) according to the manufacturer’s instructions, and 1 l was added
to a reaction mixture containing 1 PCR buffer, 1.5 mM MgCl2, 200 M
deoxynucleoside triphosphate, 0.5 M each primer, and 1 U of AmpliTaq Gold
(Applied Biosystems, Madrid, Spain). The amplification conditions were 94°C
for 10 min, and then 30 cycles of 94°C for 30 s, 55°C for 30 s, and 72°C for 1 min,
and a final elongation at 72°C for 10 min. A multiplex PCR was developed for
detecting intI1, ISCR1, and qnrA, and independent PCRs were used for detecting
qnrB, qnrS, qepA, and aac(6)-Ib-cr. Positive controls for the presence of qnrA1
(20), qnrB1 (11), qnrS1 (7), aac(6)-Ib-cr (17), and qepA1 (25) were included.
The quinolone resistance-determining regions (QRDR) of gyrA and parC and
the presence of blaLAP-1 also were screened by PCR in strains containing PMQR
genes by following previously described conditions (26, 41) and using the primers
shown in Table 1.
Amplicons were purified with a Qiaquick PCR purification kit (Qiagen, Izasa,
Barcelona, Spain). The sequencing of both strands was performed at the Mo-
lecular Genetics Unit of the University Hospital Marqués de Valdecilla using a
CEQ 2000 Dye Terminator for cycle sequencing with the Quick Start kit (Beck-
man Coulter, Inc.) or at the SCAI laboratory (Cordoba, Spain) using the Big Dye
Terminator v3.0 sequencing kit and an ABI Prism 3100 Genetic Analyzer (Ap-
plied Biosystems, Foster City, CA). The BLAST program was used to compare
the nucleotide and protein sequences to those available on the internet at the
National Center for Biotechnology Information website (www.ncbi.nlm.nih.gov).
Antimicrobial susceptibility testing. The MICs of ciprofloxacin, nalidixic acid,
ticarcillin, and ticarcillin-clavulanic acid against isolates containing PMQR genes
were determined with Etest strips (AB Biodisk, Solna, Sweden) according to the
manufacturer’s instructions. For other antimicrobial agents, MICs were deter-
mined with the MicroScan WalkAway 96 system in Santander and by the Vitek
2 system in Seville.
Molecular fingerprinting. Repetitive extragenic palindromic PCR (REP-
PCR) typing was performed on E. cloacae isolates containing PMQR genes
(Table 2). Amplicons were run in a 1.5% agarose gel for 100 min, stained with
ethidium bromide, and photographed. After visual inspection, two isolates were
considered to be clonally unrelated when two or more different bands were
observed.
Additionally, pulsed-field gel electrophoresis (PFGE) was performed on all
qnrS1-containing isolates with a CHEF-DR-II system (Bio-Rad, Hemel Hemp-
stead, United Kingdom). DNA in agarose plugs was digested overnight with
XbaI at 37°C. DNA was electrophoresed for 7 h (1- to 15-s pulse ramp) and 16 h
(15- to 35-s pulse ramp) at 14°C in a 1% agarose gel at 6 V/cm. The interpre-
tation of PFGE patterns was based on the criteria of Tenover et al. (36).
Conjugation experiments. After results of PMQR genes detection were ob-
tained (see below), one isolate of qnrS1-producing E. cloacae that was represen-
tative of each REP-PCR pattern was selected for conjugation experiments.
Matings were performed on 0.22-m nitrocellulose membranes (Millipore Cor-
poration, Billerica, MA) with E. coli J53, which is resistant to rifampin (rifam-
picin), as the recipient. After 2 h of incubation, mating mixtures were plated onto
agar containing rifampin (100 mg/liter) and ciprofloxacin (0.03 mg/liter). The
presence of qnrS1 was confirmed in the transconjugants by PCR, as described
above.
Plasmid analysis. Plasmids were detected in qnrS1-containing isolates and
derived transconjugants using DNA S1 nuclease treatment followed by PFGE as
described by Barton et al. (1). Lambda Ladder PFGE Marker from New England
Biolabs (IZASA SA, Barcelona, Spain) was used as the size marker.
Plasmid DNA of qnrS1-positive isolates and transconjugants separated in
PFGE gels was transferred onto a nylon membrane and probed for the presence
of qnrS1. The probe specific for the qnrS1 gene consisted of a 599-bp PCR
fragment amplified from whole-cell DNA of E. coli strain DH5 containing the
plasmid pBC-H2.6. The labeling of the probe and signal detection were carried
out using a DIG-High-Prime labeling and luminiscent detection kit (Roche
Diagnostics GmbH, Mannheim, Germany) according to the manufacturer’s in-
structions.
RESULTS
The qnrS1 gene was detected in 22 out of the 116 E. cloacae
isolates from Santander (19%) and was not detected in any
isolate from Seville. qnrB5 and qnrB2 were identified in two
other E. cloacae isolates. Finally, the sequencing of one of the
amplicons allowed us to identify a qnrB7-like gene (coding for
an Asp197Gly change in the corresponding QnrB7 sequence)
TABLE 1. Primers used for PCR and expected amplicon sizes
Gene or assay Primer Amplicon size (bp) Reference or source
qnrA 5-GAT AAA GTT TTT CAG CAA GAG G-3 543 10
5-ATC CAG ATC GGC AAA GGT TA-3
qnrB 5-GGC ATT GAA ATT CGC CAC TG-3 360 This study
5-TTT GCT GCT CGC CAG TCG A-3
qnrS 5-TGG AAA CCT ACA ATC ATA CA-3 599 This study
5-TGC AAT TTT GAT ACC TGA TG-3
aac(6)-Ib-cr 5-ATG ACT GAG CAT GAC CTT GC-3 519 13
5-TTA GGC ATC ACT GCG TGT TC-3
qepA 5-AAC TGC TTG AGC CCG TAG AT-3 189 This study
5-CGT GTT GCT GGA GTT CTT CC-3
intI1 5-GCG AAG TCG AGG CAT TTC TGT C-3 767 This study
5-ATG CGT GTA AAT CAT CGT CGT AGA GA-3
ISCR1 5-CGC CCA CTC AAA CAA ACG-3 469 34
5-GAG GCT TTG GTG TAA CCG-3
gyrA 5-AAA TCT GCC CGT GTC GTT GGT-3 343 41
5-GCC ATA CCT ACG GCG ATA CC-3
parC 5-ATG TAC GTG ATC ATG GAC CG-3 300 This study
5-ATT CGG TGT AAC GCA TCG CC-3
blaLAP-1 5-CAA TAC AAA GCA CAG AAG ACC-3 748 26
5-CCG ATC CCT GCA ATA TGC TC-3
REP-PCR 5-III-GCG CCG ICA TCA GGC-3 Variable 40
5-ACG TCT TAT CAG GCC TAC-3
2034 CANO ET AL. J. CLIN. MICROBIOL.






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































VOL. 47, 2009 QnrS IN ENTEROBACTER IN SPAIN 2035



























in E. aerogenes. The latter three isolates also were from San-
tander. aac(6)-Ib-cr was detected in three E. cloacae isolates
(lacking qnr genes) from Santander, and an additional isolate
of E. cloacae also carried the aac(6)-Ib gene (lacking the
mutations involved in quinolone resistance). Neither qepA nor
qnrA alleles were found in any of the tested isolates from
Santander or from Seville.
The 22 organisms containing qnrS were cultured from tra-
cheal aspirates (n 
 3), sputa (n 
 4), urine (n 
 5), blood
(n 
 1), wound exudates (n 
 5), catheter tips (n 
 2), or
abdominal drainages (n 
 2). The patients from whom E.
cloacae with qnrS1 were cultured had been admitted to 12
different wards in two different buildings of our institution.
Three patients were not hospitalized when the qnrS1-contain-
ing E. cloacae strain was isolated, including two patients on a
home health care program and one outpatient. The three iso-
lates with aac(6)-Ib-cr were cultured from urine (n 
 2) and
blood (n 
 1), while the three qnrB-containing isolates were
obtained from urine (n 
 1), blood (n 
 1), and wound exu-
dates (n 
 1).
Five REP-PCR patterns were observed among the 22 E.
cloacae isolates containing qnrS1, including 4 type A, 1 type B,
2 type C, 1 type D, and 14 type E isolates (Table 2). Types A
and C were considered possibly related by PFGE according to
Tenover’s criteria. The three E. cloacae isolates containing
aac(6)-Ib-cr were clonally unrelated, as were the two isolates
with qnrB genes. The latter two groups of organisms also were
unrelated to any of the qnrS1-containing isolates.
Data of susceptibility to quinolones of qnrS1-containing E.
cloacae isolates are presented in Table 2. A strong correlation
between the phenotype of resistance to quinolone and the
PFGE type was detected. All 14 qnrS1-positive isolates of
REP-PCR pattern E were highly resistant to both nalidixic acid
(MIC  256 g/ml) and ciprofloxacin (MIC  32 g/ml) and
contained mutations at the gyrA and parC genes that were
responsible for the changes Ser83Ile (DNA-gyrase) and Ser80Ile
(topoisomerase IV), respectively. In addition, one of these iso-
lates also contained a gyrA mutation that was responsible for the
change Asp87Asn.
The four isolates with REP-PCR pattern A were susceptible
to nalidixic acid but presented decreased susceptibility to cip-
rofloxacin. They did not contain any change at the QRDR of
gyrA and parC in comparison to the reported wild-type se-
quence of E. cloacae. In the single isolate of REP-PCR pattern
D, a mutation in gyrA (causing a Ser83Phe change) was ob-
served that correlated with resistance to nalidixic acid. The
remaining three isolates (patterns B and C) lacked any muta-
tion in the QRDR of gyrA and parC and were either susceptible
or resistant to nalidixic acid and intermediate or resistant to
ciprofloxacin (Table 2).
Transconjugants were obtained from isolates of REP-PCR
types A, C, and E. The MICs of nalidixic acid and ciprofloxacin
for the transconjugants ranged from 4 to 32 and 0.047 to 0.125
g/ml, respectively.
Plasmid analysis showed that the studied isolates possessed
one to three large plasmids, with sizes ranging from ca. 110 to
ca. 350 kb. The qnrS1 gene was associated to the 110-kb plas-
mid, although in one of three transconjugants studied, the gene
was associated with a plasmid of larger size (ca. 150 kb). As
shown in the Fig. 1, some of the transconjugants from E.
cloacae 2531 (REP-PCR pattern A) lacked the plasmid ob-
served in true transconjugants with qnrS1 and did not contain
the qnrS1 gene. As these organisms were proven by PCR to
contain qnrS1 when first isolated in the selection plate of the
conjugation assay, they may represent transconjugants that
FIG. 1. Analysis of plasmid DNA from E. cloacae parental isolates and derived transconjugants by pulsed-field agarose gel electrophoresis
(A) and Southern blotting (B). Lanes: 1, molecular marker; 2, E. cloacae 248; 3, E. cloacae 3138; 4, qnrS1-positive transconjugant from E. cloacae
3138; 5, E. cloacae 3164; 6, E. cloacae 2531; 7, transconjugant from E. cloacae 2531 lacking qnrS1; 8, qnrS1-positive transconjugant from E. cloacae
2531; 9, E. cloacae 3249; 10, E. cloacae 3049; 11, E. cloacae 3210; 12, transconjugant from E. cloacae 3210; 13, E. cloacae 1640; 14, E. cloacae 3714.
2036 CANO ET AL. J. CLIN. MICROBIOL.



























have lost the plasmid upon subculture, but further studies were
not done with these organisms.
All qnrS1-positive isolates, except the one with REP-PCR
pattern B (see below), contained the blaLAP-1 gene. However,
none of the transconjugants obtained from them was resistant
to ticarcillin (MIC, 1.5 to 3 g/ml).
Seventeen of these isolates contained the intI1 gene, two of
which also carried ISCR1. Among the 200 isolates tested, intI1
was detected in 61 isolates from Santander (58 E. cloacae and 3
E. aerogenes) and in 10 isolates from Seville (8 E. cloacae and
2 E. aerogenes). ISCR1 was detected only in E. cloacae (29 and
2 isolates in Santander and Seville, respectively).
DISCUSSION
Several previous reports indicate that PMQR genes are par-
ticularly common in E. cloacae and E. aerogenes (for a review,
see reference 18). To expand our knowledge about the distri-
bution of PMQR determinants, we screened a collection of
Enterobacter spp. from two hospitals from northern and south-
ern Spain.
There are no phenotypic markers that indicate the presence
of PMQR genes in a concrete organism. Several of the primers
we used (Table 1) were obtained from previous reports on
PMQR genes in enterobacteria. Similarly, the other primers in
that table will be helpful for a more complete study of genes
directly or indirectly related to quinolone resistance in entero-
bacteria. As the number of qnr families is increasing, a multi-
plex PCR may be used in epidemiological surveys on PMQR
genes. Previous studies indicate that strains containing PMQR
genes usually express other mechanisms of resistance; for this
reason, we included isolates that are resistant to any of the
commonly used antimicrobial agents. On the other hand, as
some qnr genes are located within a complex type 1 integron
containing int1 and ISCR1, we additionally looked for these
two genes.
Although qnrA1 was the first PMQR gene discovered, sev-
eral studies have indicated that other genes [particularly qnrS1,
some qnrB alleles, and aac(6)-Ib-cr] are more common (re-
viewed in reference 18). This was the case in this study, where
qnrS1 has been the more frequent PMQR gene, being present
in 19% of the E. cloacae isolates from Santander. In this area,
qnrB alleles and the aac(6)-Ib-cr gene also were found, but
less commonly. On the other hand, none of these genes was
detected in the Enterobacter isolates from Seville, indicating
that relevant differences in the prevalence of PMQR genes can
occur within the same country. These results may represent
differences in local resistance rates of Enterobacter (likely re-
lated to antibiotic use or infection control policies) in the two
participating centers. Because the organisms included in this
study were selected as being resistant to commonly used anti-
microbial agents, we cannot yet make clear conclusions about
the current prevalence of PMQR genes in the two regions
considered in this study. We currently are studying enterobac-
teria isolated consecutively from clinical samples (without tak-
ing into consideration their resistance profile) to obtain infor-
mation on this issue.
E. cloacae isolates containing qnrS1 were susceptible, inter-
mediate, or resistant to quinolones. Hata et al. reported (7)
that a qnrS-containing Shigella flexneri strain has changes at the
QRDR of both GyrA (Ser83Leu) and ParC (Ser80Ile). In our
case, the 14 isolates of REP-PCR pattern A presented changes
in both DNA-gyrase and topoisomerase IV, which are known
to be associated by themselves with quinolone resistance. This
is similar to what has been described for organisms containing
other PMQR genes, in which mutations in topoisomerase-
coding genes also are frequent.
On the other hand, several E. cloacae isolates (of three
different REP-PCR patterns; Table 2) lacking mutations at the
QRDR of gyrA and parC were susceptible to nalidixic acid and
presented decreased susceptibility or showed intermediate or
low-level resistance to ciprofloxacin. This pattern of resistance
is unexpected, as multiple studies previously have indicated
that enterobacteria with decreased susceptibility or intermedi-
ate resistance to fluoroquinolones are highly resistant to nali-
dixic acid. Hakanen et al. (6) described Salmonella enterica
from southeast Asia that is susceptible to nalidixic acid but
exhibits reduced susceptibility to ciprofloxacin; new studies of
this organism indicate that it contains the qnrS1 gene (2, 21).
We also have observed (3) that PMQR genes are found rather
frequently in strains susceptible to nalidixic acid and with de-
creased susceptibility to fluoroquinolones. The various levels
of resistance to ciprofloxacin in the studied isolates anticipates
that other mechanisms of resistance (such as mutations outside
the QRDR of gyrA/parC, mutations in gyrB/parE, active efflux,
or decreased permeability) or differences in gene expression
may be involved in individual isolates.
In addition to qnrS1, two E. cloacae isolates contained qnrB
alleles (qnrB5 and qnrB2), and three other isolates contained
the gene coding for the fluoroquinolone-modifying acetyltrans-
ferase Aac(6)-Ib-cr. One strain of E. aerogenes expressed a
qnrB7-like gene that coded for a protein differing from QnrB7
by (at least) a single change (Asp197Gly). Studies for deter-
mining the complete sequence of this new variant are in
progress.
As expected from our inclusion criteria, E. cloacae strains
containing qnrS1 presented different phenotypes of suscepti-
bility to antimicrobial agents other than quinolones. All intI1-
containing strains were resistant to cotrimoxazole, and some
strains were resistant to oxyminocephalosporins (10 isolates
were presumably AmpC hyperproducers, and 2 isolates pre-
sented a phenotype compatible with extended-spectrum -lac-
tamase production). The LAP-1 enzyme was detected in all
except one isolate (that with REP-PCR pattern B). The asso-
ciation of qnrS1 and blaLAP-1 already has been described (27).
Twenty-one of the 22 E. cloacae isolates with qnrS1 were re-
sistant to ticarcillin, of which 13 isolates were susceptible to
ticarcillin-clavulanic acid, a phenotype compatible with the
presence of this narrow-spectrum class A -lactamase (26).
Resistance to ticarcillin-clavulanate in the remaining nine iso-
lates should be related to other unexplored mechanisms.
The fact that qnrS1 has been found in several clonally un-
related isolates of E. cloacae is epidemiologically relevant and
indicates the potential for the spreading of this gene. Although
preliminary information suggests that the plasmid containing
qnrS1 in our isolates has disseminated to different E. cloacae
strains, it also would be possible that the plasmid was acquired
by the different strains from another organism. Two plasmids
containing qnrS1, pTPqnrS-1a (10 kb) and pK245 (98 kb), have
been completely sequenced (5, 15). The first one presents a
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region highly homologous to ColE plasmid pEC278 (from E.
coli [accession no. AY589571]) and to the qnrS1-containing
plasmid pINF5 (from Salmonella enterica serovar Infantis)
(14). The region containing qnrS1 in plasmid pK245 is 99%
identical to those of plasmids pAH0376 from S. flexneri (6) and
pINF5; pK245 also contains genes coding for SHV-2, for re-
sistance to aminoglycosides (aacC2, strA, and strB), chloram-
phenicol (catA2), sulfonamides (sul2), tetracycline (tetD), and
trimethoprim (dfrA14, within a type I integron), as well as
multiple insertion sequence elements that may facilitate the
dissemination of these resistance determinants. Many of our E.
cloacae isolates with qnrS1 contain type 1 integrons, but in the
previously characterized S. flexneri strain containing qnrS1 (7),
this gene was not contained in a type 1 integron but was in
proximity to a Tn3-like structure downstream of complete or
truncated ISEcl2 (26). Additional studies are planned to char-
acterize the involved plasmid(s) and to define the genetic back-
ground of qnrS1 in our isolates.
It also seems relevant to us that three isolates containing
qnrS1 came from nonhospitalized patients. At this moment it is
not possible to determine if these organisms had originated
in the hospital and disseminated into the community or
whether they came from the community and were imported
into the hospital. In any case, this finding reinforces the idea
of the global relationship among different compartments of
the health care system and clearly indicates a need for
additional studies looking for potential niches of bacteria
containing PMQR genes.
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